Brain GABA levels are reduced in alcoholic liver disease: A proton magnetic resonance spectroscopy study.
GABA
alcohol dependence
alcohol liver disease
baclofen
Journal
Addiction biology
ISSN: 1369-1600
Titre abrégé: Addict Biol
Pays: United States
ID NLM: 9604935
Informations de publication
Date de publication:
01 2020
01 2020
Historique:
received:
13
08
2018
revised:
07
11
2018
accepted:
08
11
2018
pubmed:
19
12
2018
medline:
11
2
2021
entrez:
19
12
2018
Statut:
ppublish
Résumé
Baclofen, a selective γ-aminobutyric acid (GABA) Proton magnetic resonance spectroscopy ( Multiple linear regression revealed that GABA+ concentration was significantly predicted by MELD scores (F = 5.02, R Severity of ALD is associated with lower cortical concentrations of GABA+. These results may explain variations in response to the GABA
Sections du résumé
BACKGROUND AND AIMS
Baclofen, a selective γ-aminobutyric acid (GABA)
METHODS
Proton magnetic resonance spectroscopy (
RESULTS
Multiple linear regression revealed that GABA+ concentration was significantly predicted by MELD scores (F = 5.02, R
CONCLUSION
Severity of ALD is associated with lower cortical concentrations of GABA+. These results may explain variations in response to the GABA
Substances chimiques
GABA-B Receptor Agonists
0
Baclofen
H789N3FKE8
Banques de données
ClinicalTrials.gov
['NCT01711125']
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e12702Subventions
Organisme : BMC Scanning Initiative
Pays : International
Organisme : National Health and Medical Research Council
Pays : International
Informations de copyright
© 2018 Society for the Study of Addiction.
Références
Bosetti C, Levi F, Lucchini F, Zatonski WA, Negri E, La VC. Worldwide mortality from cirrhosis: an update to 2002. J Hepatol. 2007;46(5):827-839.
Rehn N, Room R, Edwards GA. Alcohol in the European Region-Consumption, Harm and Policies. Copenhagen; 2001.
Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic liver diseases. J Hepatol. 2013;59(1):160-168.
Tilg H, Day CP. Management strategies in alcoholic liver disease. Nat Clin Pract Gastroenterol Hepatol. 2007;4(1):24-34.
Leggio L, Lee MR. Treatment of alcohol use disorder in patients with alcoholic liver disease. Am J Med. 2017;130(2):124-134.
Lee MR, Leggio L. Management of alcohol use disorder in patients requiring liver transplant. Am J Psychiatry. 2015;172(12):1182-1189.
Pierce M, Sutterland A, Beraha E, Morley K, Van den Brink W. Efficacy, tolerability and safety of low dose and high dose baclofen in the treatment of alcohol dependence: a systematic review and meta-analysis. Eur Neuropsychopharmacol. 2018;28(7):795-806.
Morley KC, Baillie A, Fraser I, et al. Baclofen in the treatment of alcohol dependence with or without liver disease (BacALD): a multi-site, randomised, double-blind, placebo-controlled trial. Br J Psychiatry. 2018;212(6):362-369.
Addolorato G, Leggio L, Ferrulli A, et al. Effectiveness and safety of baclofen for maintenance of alcohol abstinence in alcohol-dependent patients with liver cirrhosis: randomised, double-blind controlled study. Lancet. 2007;370(9603):1915-1922.
Behar KL, Rothman DL, Petersen KF, et al. Preliminary evidence of low cortical GABA levels in localized 1H-MR spectra of alcohol-dependent and hepatic encephalopathy patients. Am J Psychiatry. 1999;156(6):952-954.
Mon A, Durazzo TC, Meyerhoff DJ. Glutamate, GABA, and other cortical metabolite concentrations during early abstinence from alcohol and their associations with neurocognitive changes. Drug Alcohol Depend. 2012;125(1-2):27-36.
Morley KC, Lagopolous J, Logge W, Chitty K, Baillie A, Haber PS. Neurometabolite levels in alcohol use disorder patients during baclofen treatment and prediction of relapse. Front Psych. 2018;9:412.
Morley KC, Leung S, Baillie A, Haber PS. The efficacy and biobehavioural basis of baclofen in the treatment of alcoholic liver disease (BacALD): study protocol for a randomised controlled trial. Contemp Clin Trials. 2013;36(2):348-355.
Sobell LC, Maisto SA, Sobell MB, Cooper A. Reliability of alcohol abusers' self-reports of drinking behavior. Behav Res Ther. 1979;17(2):157-160.
Skinner HA, Allen BA. Alcohol dependence syndrome: measurement and validation. J Abnorm Psychol. 1982;91(3):199-209.
Mescher M, Merkle H, Kirsch J, Garwood M, Gruetter R. Simultaneous in vivo spectral editing and water suppression. NMR Biomed. 1998;11(6):266-272.
Edden RA, Puts NA, Harris AD, Barker PB, Evans CJ. Gannet: a batch-processing tool for the quantitative analysis of gamma-aminobutyric acid-edited MR spectroscopy spectra. J Magn Reson Imaging. 2014;40(6):1445-1452.
Gao F, Edden RA, Li M, et al. Edited magnetic resonance spectroscopy detects an age-related decline in brain GABA levels. Neuroimage. 2013;78:75-82.
Gao F, Edden RAE, Li M, et al. Edited magenetic resonance spectroscopy detects an age-related decline in brain GABA levels. Neuroimage. 2013;78:75-82.